Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 05 Jul 2026	HK$683.3b	HK$521.7b	HK$27.9b	13.5x	24.5x	1.3x
Tue, 02 Jun 2026	HK$662.4b	HK$522.3b	HK$29.3b	13.8x	22.6x	1.3x
Thu, 30 Apr 2026	HK$736.6b	HK$518.0b	HK$30.0b	14.5x	24.6x	1.4x
Sat, 28 Mar 2026	HK$738.2b	HK$508.9b	HK$28.3b	12x	26.1x	1.5x
Mon, 23 Feb 2026	HK$826.5b	HK$497.2b	HK$30.5b	13.1x	27.1x	1.7x
Wed, 21 Jan 2026	HK$825.0b	HK$492.7b	HK$30.2b	13x	27.3x	1.7x
Fri, 19 Dec 2025	HK$799.0b	HK$486.3b	HK$29.8b	13.2x	26.8x	1.6x
Sun, 16 Nov 2025	HK$834.0b	HK$481.8b	HK$29.9b	14.2x	27.9x	1.7x
Tue, 14 Oct 2025	HK$790.9b	HK$479.2b	HK$30.6b	13x	25.9x	1.7x
Thu, 11 Sep 2025	HK$844.5b	HK$480.0b	HK$30.6b	13.7x	27.6x	1.8x
Sat, 09 Aug 2025	HK$786.8b	HK$475.1b	HK$29.0b	11.5x	27.1x	1.7x
Mon, 07 Jul 2025	HK$661.3b	HK$476.3b	HK$28.8b	11.1x	23x	1.4x
Wed, 04 Jun 2025	HK$601.1b	HK$475.9b	HK$28.7b	11x	20.9x	1.3x
Fri, 02 May 2025	HK$507.8b	HK$467.9b	HK$28.7b	10.4x	17.7x	1.1x
Sun, 30 Mar 2025	HK$491.3b	HK$473.4b	HK$32.1b	9.2x	15.3x	1x
Tue, 25 Feb 2025	HK$454.2b	HK$463.4b	HK$31.9b	8.7x	14.2x	1x
Thu, 23 Jan 2025	HK$406.0b	HK$463.4b	HK$31.9b	8.1x	12.7x	0.9x
Sat, 21 Dec 2024	HK$431.9b	HK$460.4b	HK$31.8b	8.4x	13.6x	0.9x
Mon, 18 Nov 2024	HK$432.9b	HK$463.7b	HK$31.5b	8.2x	13.8x	0.9x
Wed, 16 Oct 2024	HK$487.3b	HK$471.2b	HK$32.7b	7.8x	14.9x	1x
Fri, 13 Sep 2024	HK$422.7b	HK$472.8b	HK$32.8b	7.3x	12.9x	0.9x
Sun, 11 Aug 2024	HK$440.9b	HK$463.5b	HK$32.9b	7.4x	13.4x	1x
Tue, 09 Jul 2024	HK$433.5b	HK$461.3b	HK$33.7b	7.6x	12.9x	0.9x
Thu, 06 Jun 2024	HK$471.2b	HK$463.6b	HK$33.9b	8.3x	13.9x	1x
Sat, 04 May 2024	HK$475.2b	HK$463.4b	HK$33.7b	7.6x	14.1x	1x
Mon, 01 Apr 2024	HK$445.8b	HK$465.7b	HK$36.5b	7.7x	12.2x	1x
Wed, 28 Feb 2024	HK$448.3b	HK$470.7b	HK$33.5b	7.7x	13.4x	1x
Fri, 26 Jan 2024	HK$426.9b	HK$471.9b	HK$33.7b	7.2x	12.7x	0.9x
Sun, 24 Dec 2023	HK$464.0b	HK$472.7b	HK$33.8b	7.5x	13.7x	1x
Tue, 21 Nov 2023	HK$508.8b	HK$471.7b	HK$32.2b	7.1x	15.8x	1.1x
Thu, 19 Oct 2023	HK$432.0b	HK$469.1b	HK$31.5b	6.9x	13.7x	0.9x
Sat, 16 Sep 2023	HK$424.5b	HK$470.0b	HK$31.6b	6.7x	13.4x	0.9x
Mon, 14 Aug 2023	HK$439.9b	HK$446.6b	HK$28.2b	8.6x	15.6x	1x
Wed, 12 Jul 2023	HK$478.1b	HK$446.4b	HK$27.9b	9.5x	17.2x	1.1x

Current Industry PE

Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 24.5x which is higher than its 3-year average PE of 18.3x.

The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.3x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
Meanwhile revenues for these companies have grown 5.3% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	1.13%
Healthcare	13.75%
Pharma	13.55%
Pharma	13.55%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
3692 Hansoh Pharmaceutical Group	HK$33.70	17.6% +HK$30.6b	8.2%	PE31.8x
1093 CSPC Pharmaceutical Group	HK$8.00	19.6% +HK$15.0b	-1.8%	PE24.2x
1177 Sino Biopharmaceutical	HK$4.74	11.3% +HK$8.6b	-15.4%	PE31.2x
2096 Simcere Pharmaceutical Group	HK$11.47	23.7% +HK$5.7b	4.1%	PE19x
867 China Medical System Holdings	HK$11.53	16.1% +HK$3.9b	-5.8%	PE16.2x

Company

Last Price

Valuation

3692 Hansoh Pharmaceutical Group

HK$33.70

17.6%
+HK$30.6b

8.2%

PE31.8x

1093 CSPC Pharmaceutical Group

HK$8.00

19.6%
+HK$15.0b

-1.8%

PE24.2x

1177 Sino Biopharmaceutical

HK$4.74

11.3%
+HK$8.6b

-15.4%

PE31.2x

2096 Simcere Pharmaceutical Group

HK$11.47

23.7%
+HK$5.7b

4.1%

PE19x

867 China Medical System Holdings

HK$11.53

16.1%
+HK$3.9b

-5.8%

PE16.2x

Sino Biopharmaceutical Limited Submits New Drug Application for Ropivacaine Hydrochloride Sustained-Release Solution

The board of directors of Sino Biopharmaceutical Limited announced that a new drug application for ropivacaine hydrochloride sustained-release solution, a national Category 2.2 new drug independently developed by Beijing Tide Pharmaceutical Co. Ltd., a subsidiary of the Group, has been submitted to and accepted by the Center for Drug Evaluation of China's National Medical Products Administration, for postoperative long-acting analgesia in adults. This drug is the world's first novel long-acting ropivacaine analgesic administered via intra-incisional instillation. Ropivacaine hydrochloride is the first pure levorotatory long-acting amide-type local anesthetic. At high doses, it can produce surgical anesthesia, while at low doses, it can provide the effect of sensory blockade (analgesia). It blocks axonal sodium influx and inhibits neuronal membrane depolarization, thereby interrupting action potential propagation and blocking pain signal transmission. Compared with bupivacaine, a drug in the same class, ropivacaine hydrochloride offers clinical advantages of lower cardiotoxicity and a more pronounced separation of motor and sensory blockade. Ropivacaine hydrochloride sustained-release solution is a novel long-acting non-opioid analgesic, developed using a proprietary lipid-based targeted injection technology platform. The drug features an innovative intra-incisional instillation administration, topically applied before wound closure. The straightforward application procedure helps shorten healthcare professionals' operation time and significantly improves clinical convenience. Leveraging its advanced formulation, the drug undergoes a phase transition upon contact with tissue fluid at the administration site, forming a drug reservoir that enables sustained drug release for up to 72 hours. Compared with conventional multi-site infiltration administration, this drug significantly reduces systemic exposure, with a superior safety profile. Results from two pivotal Phase III registrational clinical trials showed that in unilateral hip replacement (somatic pain model) and abdominal surgery (somatic/visceral mixed pain model), a single administration of ropivacaine hydrochloride sustained-release solution provided sustained analgesia for up to 72 hours, significantly reducing the dose and frequency of rescue analgesic use. The analgesic efficacy was significantly superior to that of the active control, and the overall safety profile was good. Pharmacokinetic studies indicate that this drug exhibits sustained-release characteristics, including delayed absorption, lower peak serum concentrations, a longer plateau phase at peak concentration, lower systemic exposure, and a gradual elimination process, further confirming its clinical value in prolonging analgesic duration, enhancing safety, and improving compliance. The acceptance of the marketing application for ropivacaine hydrochloride sustained-release solution will further enrich the Group's product portfolio in the area of long-acting analgesia and enhance its postoperative pain management franchise. This drug offers a differentiated and complementary alternative to the Group's existing marketed products and can be used in combination in clinical settings, helping to optimize postoperative pain management regimens and further consolidate the Group's competitiveness and market position in the analgesia space.

Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Sino Biopharmaceutical Limited Submits New Drug Application for Ropivacaine Hydrochloride Sustained-Release Solution

Hansoh Pharmaceutical Gains NMPA Approval for New Diabetes and Weight Management Trial

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Vigonvita Life Sciences Co., Ltd. Announces Board and Committee Changes

Investor sentiment improves as stock rises 18%

Wai Yuen Tong Medicine Holdings Limited, Annual General Meeting, Aug 19, 2026

Shaanxi Micot Pharmaceutical Technology Co., Ltd. has completed an IPO in the amount of HKD 1.05659 billion.

New minor risk - Share price stability

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2025

Investor sentiment improves as stock rises 20%

Tennor Therapeutics (Suzhou) Limited Appoints Song Gaoguang as Member of Remuneration and Appraisal Committee, Effective June 8, 2026

Modern Chinese Medicine Group Co., Ltd., Annual General Meeting, May 29, 2026

Zhongzhi Pharmaceutical Holdings' (HKG:3737) Weak Earnings May Only Reveal A Part Of The Whole Picture